TY  - JOUR
AU  - Hertler, Caroline
AU  - Felsberg, Jörg
AU  - Gramatzki, Dorothee
AU  - Le Rhun, Emilie
AU  - Clarke, Jennifer
AU  - Soffietti, Riccardo
AU  - Wick, Wolfgang
AU  - Chinot, Olivier
AU  - Ducray, François
AU  - Roth, Patrick
AU  - McDonald, Kerrie
AU  - Hau, Peter
AU  - Hottinger, Andreas F
AU  - Reijneveld, Jaap
AU  - Schnell, Oliver
AU  - Marosi, Christine
AU  - Glantz, Michael
AU  - Darlix, Amélie
AU  - Lombardi, Giuseppe
AU  - Krex, Dietmar
AU  - Glas, Martin
AU  - Reardon, David A
AU  - van den Bent, Martin
AU  - Lefranc, Florence
AU  - Herrlinger, Ulrich
AU  - Razis, Evangelia
AU  - Carpentier, Antoine F
AU  - Phillips, Samuel
AU  - Rudà, Roberta
AU  - Wick, Antje
AU  - Tabouret, Emeline
AU  - Meyronet, David
AU  - Maurage, Claude-Alain
AU  - Rushing, Elisabeth
AU  - Rapkins, Robert
AU  - Bumes, Elisabeth
AU  - Hegi, Monika
AU  - Weyerbrock, Astrid
AU  - Aregawi, Dawit
AU  - Gonzalez-Gomez, Christian
AU  - Pellerino, Alessia
AU  - Klein, Martin
AU  - Preusser, Matthias
AU  - Bendszus, Martin
AU  - Golfinopoulos, Vassilis
AU  - von Deimling, Andreas
AU  - Gorlia, Thierry
AU  - Wen, Patrick Y
AU  - Reifenberger, Guido
AU  - Weller, Michael
TI  - Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders' Collaborative Consortium (EORTC 1419).
JO  - European journal of cancer
VL  - 189
SN  - 0014-2964
CY  - Amsterdam [u.a.]
PB  - Elsevier
M1  - DKFZ-2023-01107
SP  - 112913
PY  - 2023
N1  - Volume 189, August 2023, 112913
AB  - Median survival with glioblastoma remains in the range of 12 months on population levels. Only few patients survive for more than 5 years. Patient and disease features associated with long-term survival remain poorly defined.European Organization for Research and Treatment of Cancer (EORTC) 1419 (ETERNITY) is a registry study supported by the Brain Tumor Funders Collaborative in the US and the EORTC Brain Tumor Group. Patients with glioblastoma surviving at least 5 years from diagnosis were identified at 24 sites in Europe, US, and Australia. In patients with isocitrate dehydrogenase (IDH) wildtype tumours, prognostic factors were analysed using the Kaplan-Meier method and the Cox proportional hazards model. A population-based reference cohort was obtained from the Cantonal cancer registry Zurich.At the database lock of July 2020, 280 patients with histologically centrally confirmed glioblastoma (189 IDH wildtype, 80 IDH mutant, 11 incompletely characterised) had been registered. In the IDH wildtype population, median age was 56 years (range 24-78 years), 96 patients (50.8
KW  - IDH (Other)
KW  - MGMT (Other)
KW  - Outcome (Other)
KW  - Prognosis (Other)
KW  - Registry (Other)
KW  - Wildtype (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37277265
DO  - DOI:10.1016/j.ejca.2023.05.002
UR  - https://inrepo02.dkfz.de/record/276424
ER  -